United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Small biotech outlet BioNTech will partner with pharma powerhouse Pfizer to develop a coronavirus vaccine, the companies said Tuesday — sending BNTX stock flying for a second day running.
The post Covid Report: Biotech IPO Breaks Out On Pfizer Deal For Coronavirus Drug appeared first on Investor's Business Daily.

Covid Report: Biotech IPO Breaks Out On Pfizer Deal For Coronavirus Drug

BioNTech SE

Pfizer Inc. PFE, -7.73% said Tuesday it will help develop and distribute BioNTech SE's COVID-19 vaccine candidate, though the deal excludes China.

BioNTech, Pfizer to develop COVID-19 vaccine candidate

NEW YORK and MAINZ, Germany, March  17, 2020  (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech) today announced that the companies have agreed to a letter of intent regarding the co-development and distribution (excluding China) of a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection. The companies have executed a Material Transfer and Collaboration Agreement to enable the parties to immediately start working together.

Pfizer and BioNTech to Co-develop Potential COVID-19 Vaccine

Pfizer's deep ties to China are weighing on its shares today.

Why Pfizer Stock Is Tumbling Today

Pfizer (PFE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Pfizer (PFE) Catches Eye: Stock Jumps 9%

Pfizer’s stock will likely outperform in the current coronavirus and oil price war crisis. So far, it has fared better than the broader markets, with the stock currently down by 19% since early February, after the WHO declared a global health emergency.In comparison, the S&P 500 is down by about 25%

Will Pfizer Stock Outperform The Broader Market Post Coronavirus?

Teleworking is a good way to reduce the chance of spreading infection.

Pfizer Tells Entire Salesforce to Work Remotely Due To Coronavirus Pandemic

The pharma giant is helping any way it can.

Pfizer Outlines Plans to Help With the COVID-19 Outbreak

Pfizer joins a growing number of companies that are mandating that employees remain at home.

Pfizer tells all US salespeople they must work remotely

GlaxoSmithKline

In the battle between these pharma heavyweights, which one’s prospects shine brightest?

Better Buy: Pfizer vs. GlaxoSmithKline

Pfizer has seriously underperformed in recent years. Down 10.8% year to date, Pfizer stock remains an underdog.

Pfizer Stock Remains a Cautionary Tale For Investors

Cisco Systems

Intel

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Exxon Mobil

March 11, 2020 7:05 am
It takes a certain kind of courage to short sell blue chips, such as the Dow Jones industrial average components. Short sellers are betting on these companies to fail, or at least for their share prices to fall handily.

The 5 Most  Shorted Dow Stocks

Cocrystal Pharma

Gilead Sciences

Inovio Pharmaceuticals

Johnson & Johnson

Moderna

NanoViricides

Novavax

Sanofi

Vaxart

The COVID-19 virus has sent the market and the global economy into a tailspin. The Organisation for Economic Co-operation and Development slashed its global growth forecast for 2020 Monday by 0.5 points to 2.5% versus already-weak 2.9% growth in 2019.

How Close Are Biotechs To Bringing A COVID-19 Treatment To Market?

The drug combination has to be injected, but only having to deal with treatment once a month could be worth it for many patients.

Pfizer, GlaxoSmithKline, Johnson & Johnson Team Up on Once-Monthly HIV Treatment

Pfizer stock is gearing up for a strong 2020 as the company spins out is generics drug business, completing a merger with Mylan.
The post Its Powerful Pipeline Shows Pfizer Stock Is Undervalued by 15% appeared first on InvestorPlace.

Its Powerful Pipeline Shows Pfizer Stock Is Undervalued by 15%

Regeneron Pharmaceuticals

7 Big Pharma Companies Trump Asked to Fight the Coronavirus Outbreak

Pfizer's stock can't escape Monday's blood bath in the markets.

Why Pfizer Stock Is Plunging Today

Pfizer stock is on a recent downswing in the wake of lackluster fourth-quarter earnings. Is the pharmaceutical company a buy right now?

Pfizer Sacrificed A Buy Point Amid Coronavirus Woes — Is It A Buy Now?

Pfizer At Attractive Valuation

AbbVie

Agenus

Aphria

Atreca

Bicycle Therapeutics Plc - ADR

Bristol-Myers

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals Inc

Amicus Therapeutics

GW Pharmaceuticals

OrganiGram Holdings Inc.

Arcus Biosciences

Sarepta Therapeutics

The coronavirus induced sell-off has created a number of attractive buying opportunities.

These 14 Stocks Are Stupid Cheap

Pfizer stock had a good day on Wednesday, but remains a bad bet for investors. The Mylan-Upjohn spinoff later this year will sap its value.

Pfizer Won’t Win the Coronavirus Pharma War

Pfizer's various commercial links to China weighed on its shares last month.

Why Pfizer Stock Tanked in February

Pfizer (PFE) identifies potential antiviral compounds to develop a treatment for coronavirus disease. The FDA accepts regulatory application seeking approval for tanezumab for osteoarthritis.

Pfizer Plans Coronavirus Therapy, Progresses With Tanezumab BLA

Investors need to pay close attention to Pfizer (PFE) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Pfizer (PFE) Stock?

Pfizer Inc. (NYSE: PFE) says it is in the process of working with a third party to screen compounds that may curb coronaviruses.

Pfizer Works On Compounds That May Help Stop Coronaviruses

News for Pfizer Stock (PFE)